Tissue Regenix Group PLC Result of AGM

RNS Number : 0853M

Tissue Regenix Group PLC

25 April 2024

 

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Group', or the 'Company')

 

Result of Annual General Meeting

 

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces that at the Annual General Meeting ('AGM') held earlier today, all resolutions were duly passed on a show of hands.

 

The results of the proxy votes received in respect of the resolutions, given to the Chair prior to the meeting, are set out below:

 

Resolution		In favour	%	Against	%	Withheld
1	Ordinary	30,257,029	99.99	610	0.01	12,274
2	Ordinary	30,249,468	99.98	7,296	0.02	13,149
3	Ordinary	30,254,468	99.99	2,296	0.01	13,149
4	Ordinary	30,254,468	99.99	2,296	0.01	13,149
5	Ordinary	30,254,968	99.99	1,796	0.01	13,149
6	Ordinary	30,254,468	99.99	2,296	0.01	13,149
7	Ordinary	30,254,468	99.99	2,296	0.01	13,149
8	Ordinary	30,255,203	99.99	1,561	0.01	13,149
9	Ordinary	30,255,203	99.99	2,436	0.01	12,274
10	Ordinary	30,253,968	99.96	11,671	0.04	4,274
11	Special	30,049,183	99.28	216,456	0.71	4,274
12	Special	30,236,441	99.93	21,198	0.07	12,274

 

 

Notes:

1.     A "Vote withheld" is not counted in the calculation of the percentage of shares voted "In favour" or "Against".

2.     As at 23 April 2023, being the voting deadline date in respect of the Annual General Meeting, the total number of Ordinary Shares of 0.1p each in issue and the total number of voting rights was 70,574,468.

 

The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 19 March 2024.

 

For more information:

 

Tissue Regenix Group plc		www.tissueregenix.com
David Cocke, Chief Financial Officer		via Walbrook PR
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR)	Tel: [phone]
Alice Woodings/Charlotte Edgar	[e-mail]

 

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

RAGSEMFDIELSEEL